Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use. Therefore, we evaluated letermovir, a novel antiviral agent recently approved for use in hematopoietic cell transplant patien...

Full description

Bibliographic Details

Published in:	Transplantology
Main Authors:	Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Subjects:	lung transplant cytomegalovirus letermovir valganciclovir leukopenia
Online Access:	https://www.mdpi.com/2673-3943/2/2/13